이전|다음

"복사" 이론에 기반한 범혈관질환 발병 기전 및 예방 치료 전략 탐구

  • role： First author第一作者
  • Affiliation：

    Guang'anmen Hospital， China Academy of Chinese Medical Sciences， Beijing 100053，China

  • Email：zhangruoqi126@126.com
  • Introduction：张若琪，在读博士，从事中西医结合防治心血管疾病研究，E-mail：zhangruoqi126@126.com
ZHANG Ruoqi,  
  • role： Corresponding author通信作者
  • Affiliation：

    Guang'anmen Hospital， China Academy of Chinese Medical Sciences， Beijing 100053，China

  • Email：wangjie0103@126.com
  • Introduction：王阶，博士生导师，主任医师，全国名中医，从事中西医结合防治心血管疾病研究，E-mail：wangjie0103@126.com
WANG Jie*,  
  • Affiliation：

    Guang'anmen Hospital， China Academy of Chinese Medical Sciences， Beijing 100053，China

LIU Lanchun,  
  • Affiliation：

    Guang'anmen Hospital， China Academy of Chinese Medical Sciences， Beijing 100053，China

LIU Chao

추상적인

범혈관질환은 동맥경화를 주요 병리적 특징으로 하는 전신성 혈관 질환으로, 심장, 뇌, 신장, 사지 및 대동맥 등 여러 기관의 혈관망에 영향을 미칩니다. 이 질환 개념은 전통적인 분과의 한계를 뛰어넘어 다학제 협력을 통해 종합적인 혈관 건강 관리를 실현합니다. "복사"는 범혈관질환의 발병 기전에 중요한 역할을 하며, 체내에 잠복하여 기회를 엿보다가 발병하는데, 이는 범혈관질환의 초기 잠복 진행과 후기에 불량 혈관 사건이 발생하는 특징과 높은 일치성을 보입니다. 본 논문은 "복사" 이론을 기반으로 범혈관질환의 "사기잠복-맥손-정상손상" 발병 기전을 설명하고, 질병 발생이 기와 혈의 병리 과정이며, 내피 손상이 시작 요인임을 제시합니다; 질병 진행은 혈액의 맥 내 병리적 변화가 존재하며, 염증 반응이 질병 과정을 가속화합니다. 중의약 전 과정 예방치료 체계를 구축하여 질병 경과를 세 단계로 나누었으며, 조기에는 사기가 맥도를 잠복하고 주요 병리 기전은 지질대사 이상, 중기에는 사기가 진행하여 생변하며 주요 병리 기전은 염증 연쇄 반응, 후기에는 사기가 성하고 정상기가 쇠약해지며 주요 병리 기전은 에너지대사 이상입니다. 주요 병리 고리를 중심으로 비위강화화담, 활혈화어, 부정보허 세 가지 치료법을 확립하고, 현대 의학 연구와 병행하여 지질대사 조절, 염증 반응 억제, 에너지 대사 조절을 통한 범혈관질환의 예방치료 기전을 설명합니다. 이 이론 체계가 범혈관질환의 중의 변증치법 사상을 풍부하게 하고, 중의학 특색의 범혈관질환 예방치료 방안 구축에 이론적 지지를 제공하기를 기대합니다.

키워드

복사;범혈관질환;중의약;병기;예방 치료 전략

References

  1. 1.
    YANG J，WANG K Q，HUO Y，et al.Scientific statement for the prevention and treatment of panvascular disease［J］.Chin Circ J，2019，34（11）：1041-1046.
  2. 2.
    National Center for Cardiovascular Diseases， The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on cardiovascular health and diseases in China 2024：An updated summary［J］.Chin Circ J，2025， 40（6）：521-559.
  3. 3.
    PAN Y S，JING J，CAI X L，et al.Prevalence and vascular distribution of multiterritorial atherosclerosis among community dwelling adults in Southeast China［J］.JAMA Netw Open，2022，5（6）：e2218307.
  4. 4.
    ALBERTS M J，BHATT D L，MAS J L，et al.Three year follow up and event rates in the international reduction of atherothrombosis for continued health registry［J］.Eur Heart J，2009，30（19）：2318-2326.
  5. 5.
    ZHANG S X，LIU Z，ZHAO Y M，et al.Discussion on the pathogenesis of pan-vascular diseases based on the theory of "stagnation due to Qi deficiency"［J］.J Beijing Univ Tradit Chin Med，2024，47（7）：983-988.
  6. 6.
    LI J，SUN Y N，WANG J.Thinking of Traditional Chinese Medicine in prevention and treatment of panvascular diseases based on ''blood vessel-Zangfu organ-syndrome differentiation and treatment''［J］.Chin J Exp Tradit Med Form，2024，30（10）：187-195.
  7. 7.
    ZHANG C C，TANG S J.Theory of hidden pathogen and the theory of five evolutive phases and six climatic factors［J］.Chin J Tradit Chin Med Pharm，2021，36（5）：2597-2600.
  8. 8.
    ZHANG Y X，LIU Y X，ZHANG S，et al. Development of the hidden pathogen theory in Huangdi Neijing by famous TCM doctors in northeast China［J］.Chin J Tradit Chin Med Pharm，2025，40（4）：2026-2029.
  9. 9.
    WANG J，LI J，DONG Y，et al. Traditional Chinese medicine connotation and prevention strategies for panvascular diseases［J］.Chin J Exp Tradit Med Form，2025，31（7）：1-14.
  10. 10.
    WANG J，HU J，LI J，et al."Kidney deficiency-vessel impairment" as core pathogenesis of panvascular diseases：Theoretical and clinical perspectives［J］.Chin J Chin Mater Med，2025，50（13）：3513-3521.
  11. 11.
    XU S W，GE J B，WENG J P.Endothelial dysfunction and panvascular diseases［J］.J Univ Sci Technol China，2021，51（8）：577-585.
  12. 12.
    WEI S L，ZHOU Y W，XU S W，et al.Risk factors of pan-vascular diseases and their interactions［J］.Biomed Transf，2024，5（4）：113-124.
  13. 13.
    ZHANG Q，LIU J，DUAN H，et al.Activation of Nrf2/HO-1 signaling：An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress［J］.J Adv Res，2021，34：43-63.
  14. 14.
    LI Y H，ZHOU M Z，LI H Q，et al.Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways［J］.Eur Heart J，2024，45（4）：268-283.
  15. 15.
    CHEN R K，ZHANG H R，TANG B T，et al.Macrophages in cardiovascular diseases：Molecular mechanisms and therapeutic targets［J］.Sig Transduct Target Ther，2024，9（1）：130.
  16. 16.
    DE MEYER G R Y，ZUREK M，PUYLAERT P，et al.Programmed death of macrophages in atherosclerosis：Mechanisms and therapeutic targets［J］.Nat Rev Cardiol，2024，21（5）：312-325.
  17. 17.
    GUO Z Y，ZHANG W，GAO H Xet al.High expression levels of haem oxygenase-1 promote ferroptosis in macrophage-derived foam cells and exacerbate plaque instability［J］.Redox Biol，2024，76：103345.
  18. 18.
    DAI R， LEI X T， LIU X J， et al. UQCRB regulates mitochondrial energy metabolism by promoting COX5 A in atherosclerotic endothelial dysfunction［J］. Naunyn Schmiedebergs Arch Pharmacol，2025，398（11）：16181-16193.
  19. 19.
    ZHANG Y W，LAN Y Y，WU S T.Differentiation and treatment of hyperthyroidism based on clinical staging according to the transmission law of "Qi - blood - vessels"［J］.Glob J Tradit Chin Med，2025，18（3）：575-578.
  20. 20.
    ZHOU Z，LIU Y，WANG Z，et al.Differentiation and treatment of myocardial reperfusion injury after percutaneous coronary intervention based on the "vascular theory"［J］.J Chin Med Pharmacol，2022，50（12）：1-4.
  21. 21.
    WANG H H，SONG Y，HE F，et al.Exploration on the correlation between circulating tumor cells and recurrence and metastasis of colorectal cancer based on the theory of latent pathogens［J］.J Tradit Chin Med，2024，65（19）：1983-1987.
  22. 22.
    LI H R，WU Y L.Inheritance and innovation of Luobing research［J］.J Nanjing Univ Tradit Chin Med，2022，38（12）：1075-1085.
  23. 23.
    WU Y L.Analysis on etiology of collateral disease［J］.J Diffic Complicat Case，2004（4）：215-217.
  24. 24.
    WEBER C，HABENICHT A J R，VON HUNDELSHAUSEN P.Novel mechanisms and therapeutic targets in atherosclerosis：Inflammation and beyond［J］.Eur Heart J，2023，44（29）：2672-2681.
  25. 25.
    BRÄUNINGER H，KRÜGER S，BACMEISTER L，et al.Matrix metalloproteinases in coronary artery disease and myocardial infarction［J］.Basic Res Cardiol，2023，118（1）：18.
  26. 26.
    DIB L，KONEVA L A，EDSFELDT A，et al.Lipid-associated macrophages transition to an inflammatory state in human atherosclerosis increasing the risk of cerebrovascular complications［J］.Nat Cardiovasc Res，2023，2（7）：656-672.
  27. 27.
    GAWAZ M，GEISLER T，BORST O.Current concepts and novel targets for antiplatelet therapy［J］.Nat Rev Cardiol，2023，20（9）：583-599.
  28. 28.
    LI J W，LI X Y，SONG S J，et al.Mitochondria spatially and temporally modulate VSMC phenotypes via interacting with cytoskeleton in cardiovascular diseases［J］.Redox Biol，2023，64：102778.
  29. 29.
    NATARAJAN N，FLORENTIN J，JOHNY E，et al.Aberrant mitochondrial DNA synthesis in macrophages exacerbates inflammation and atherosclerosis［J］.Nat Commun，2024，15（1）：7337.
  30. 30.
    JIN Y，LIU Y，XU L，et al.Novel role for Caspase 1 inhibitor VX765 in suppressing NLRP3 inflammasome assembly and atherosclerosis via promoting mitophagy and efferocytosis［J］.Cell Death Dis，2022，13（5）：512.
  31. 31.
    LIU C.Clinical and mechanistic study on Bushen Huoxue decoction in treating coronary heart disease with kidney deficiency and blood stasis syndrome by regulating the lncRNA NEAT1/miR-139-5p/Fos axis［D］.Beijing：Beijing University of Chinese Medicine，2022.
  32. 32.
    CHEN Y F，HE Q Y，LIU C，et al.Clinical observation on coronary heart disease angina pectoris patients with syndrome of binding of static blood and heat intervened by Qingre Huoxue decoction［J］.Chin J Tradit Chin Med Pharm，2017，32（9）：4288-4291.
  33. 33.
    CHEN Z.Study on the inflammatory protective mechanism of Huoxue Huatan decoction on rats with coronary heart disease of phlegm-stasis interbinding syndrome via the miR-223/PPRs pathway［D］.Beijing：Beijing University of Chinese Medicine，2016.
  34. 34.
    HUANG M Y，CHEN G，GAO J L，et al.The theory and practice of preventing diseases based on the whole process of coronary heart disease management［J］.Chin J Clin Health，2019，22（6）：860-864.
  35. 35.
    YANG W J，WANG T T，ZHU Y W，et al.Research of the formulation rules for prescriptions containing Atractylodis Macrocephalae Rhizoma-Poria drug pair based on data mining［J］.Chin J Mod Appl Pharm，2024，41（14）：1980-1988.
  36. 36.
    WANG Q G，CAO Y，SONG N，et al.Effects of Pachyman on liver lipid deposition and expression of reverse cholesterol transport related proteins in ApoE-/-AS mice［J］.World Sci Technol - Mod Tradit Chin Med，2022，24（7）：2637-2643.
  37. 37.
    TANG Q J，CHEN S H，PAN D D，et al.Preliminary study on efficacy and mechanism of Atractylodes Macrocephelae Rhizoma extracts in metabolic hyperlipidemia rats［J］.China J Chin Mater Med，2015，40（9）：1803-1807.
  38. 38.
    HE D Q.Tanshinone ⅡA ameliorates inflammatory response in atherosclerosis by regulating the Hippo-YAP signaling pathway［D］.Guangzhou：Southern Medical University，2023.
  39. 39.
    WANG Y Y，WANG C，HU R，et al.Mechanism of Danshen-Chuanxiong medicinal pair in the treatment of atherosclerosis based on network pharmacology and in vitro experiment［J］.Pharmacol Clin Chin Mater Med，2022，38（4）：67-73.
  40. 40.
    MENG Y，LI J.On etiology，syndrome and treatment of sequelae of pelvic inflammatory disease from the perspective of "where pathogens gather，Qi must be deficient"：Experience from learning classics and practicing clinical medicine［J］.Neimonggu J Tradit Chin Med，2019，38（2）：96-97.
  41. 41.
    LI Y.Interventional effect of Qi-boosting drugs on myocardial energy metabolism remodeling in rat models with chronic heart failure and heart Qi deficiency syndrome［D］.Beijing：Beijing University of Chinese Medicine，2012.
  42. 42.
    PARK K，LI Q，LYNES M D，et al.Endothelial cells induced progenitors into brown fat to reduce atherosclerosis［J］.Circ Res，2022，131（2）：168-183.
  43. 43.
    CHENG N，WANG J，LIU L C，et al.Effects of Huoxue Bushen Anshen prescription on energy metabolism of H9c2 cardiomyocytes with oxidative stress injury［J］.Chin J Inf Tradit Chin Med，2024，31（9）：94-101.
  44. 44.
    HE X，JIN X L，KANG X N，et al.To explore the drug syndrome types and mechanism of perivascular disease based on hidden structure and network pharmacology［J］.Sci Technol Eng，2024，24（18）：7574-7583.

더 읽기

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website